Abstract
Mucormycosis (MCR) is a fulminant, potentially lethal, opportunistic fungal infection. Diabetes, immunocompromised states and elevated serum iron levels are the most important risk factors for contracting MCR infection. Recently, MCR co-infections have been observed in patients with COVID-19 disease owing to a complex interplay of metabolic factors and corticosteroid therapy. Rhino-orbito-cerebral mucormycosis (ROCM) is the most common clinical form of MCR infection and refers to infection of the nasal cavities, paranasal sinuses, neck spaces, orbits and intracranial structures. Sinonasal inoculation is typically the primary site of infection; the necrotising and angioinvasive properties of the fungus facilitate its spread into adjacent structures. In this review, we discuss the pertinent mycology and risk factors of MCR infection. The review also aims to acquaint the reader with the cross-sectional imaging appearances of ROCM and its complications. All the cases discussed in this pictorial essay are microbiologically and/or histopathologically proven cases of ROCM with concomitant COVID-19 infection.
Keywords: Mucormycosis, Rhino-orbito-cerebral Mucormycosis, Invasive fungal sinusitis
Key points
Rhino-orbito-cerebral Mucormycosis is potentially fatal; mortality depends on the extent of spread.
Cross-sectional imaging provides quick, presumptive diagnosis and guides management.
The “black turbinate” sign is a common imaging finding, but is not specific.
Angioinvasion facilitates rapid extra-sinus spread without overt bone destruction.
Perineural spread constitutes an important pathway for intracranial spread.
Background
Mucormycosis (MCR) is an opportunistic infection caused by fungi belonging to order Mucorales [1]. Frequently reported species belong to genera Rhizopus, Lichtemia and Mucor [2]. These fungi are saprophytic and commonly found in soil, decaying food and excrements [3] (Fig. 1). Human infection mainly occurs due to inhalation of spores; ingestion of contaminated food and traumatic inoculation are uncommon modes of transmission [4]. The hallmark of MCR infection is angioinvasion leading to vascular thrombosis, widespread tissue necrosis and systemic dissemination [5].
Risk factors
Diabetes mellitus (DM) is a major predisposing factor in MCR infection. DM reduces immunity making patients susceptible to infection [6]. The incidence of MCR in patients with DM ranges between 17% and 88% globally [4]. In fact, 70% patients with ROCM are found to have underlying DM [7]. Elevated free serum iron and deferoxamine chelation therapy are also known to increase the risk of MCR [5, 7].
MCR is also common among patients with neutropenia. 2%–15% cases of MCR are seen in patients with solid organ malignancies and organ transplants [4]. Immunosuppressive therapies, especially high-dose steroid (≥ 600 mg prednisone), used in the management of malignancies, transplantation and autoimmune conditions, also increase the risk of MCR [4, 8]. Patients who receive prophylactic antifungal therapy have been identified as an important risk group for MCR [4, 8]. Breakthrough MCR was first reported with voriconazole prophylaxis and subsequently with other triazoles [4, 8]. Voriconazole is a broad spectrum antifungal that does not inhibit Mucorales [7]. The inhibition of other fungi and overall improved life expectancy of immunosuppressed patients have been hypothesised to increase risk of MCR infection [7].
Other risk factors include HIV infection, intravenous drug abuse, malnutrition, chronic alcoholism, liver disease and treatment with calcineurin inhibitors [4]. MCR may occur in immunocompetent patients suffering from burns, following major trauma or through contaminated surgical material [4].
COVID-19 and the risk of Mucormycosis
The coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While most of the clinical manifestations and complications of COVID-19 have been documented with standardised treatment protocols, multiple fungal opportunistic infections have now emerged as the new threat to a favourable prognosis. Of these a steady surge of MCR co-infections has been observed leading to the coinage of the term COVID-19-associated Mucormycosis (CAM) [9, 10].
Corticosteroids used in the management of COVID-19 have been identified as a potential risk factor for MCR infection, due to the induced reduction of immune function and altered glucose homeostasis. In addition severe COVID-19 disease has been associated with a hyperferritinemic syndrome increasing the risk of cellular damage and increased free iron ultimately increasing the risk of MCR [11, 12]. The rampant use of supplements containing zinc and iron, both nutrients for Mucorales, has also been speculated in the rise of CAM. Sen et al. suggested that ROCM occurred in patients with severe COVID-19 disease, those admitted to the intensive care unit or requiring mechanical ventilation [13]. Banerjee et al. proposed that the inadvertent use of industrial oxygen, reusable oxygen humidifiers and poor sanitation may also contribute to ROCM in COVID-19 patients.
Rhino-orbito-cerebral mucormycosis (ROCM)
ROCM describes a fulminant infection of the nasal cavities, paranasal sinuses, neck spaces, orbits and intracranial structures caused by Mucorales species. ROCM presents in an acute setting, similar to sinusitis [14]. Fever, facial pain, facial swelling, headache, nasal discharge, nasal ulceration and palatal ulceration are common presenting features [15]. Foul smelling, black, necrotic eschar of the nasal mucosa or palate is seen in about 50% cases, but is a sentinel sign of ROCM [14, 16]. This necrotic black tissue occurs due to local vascular thrombosis and tissue infarction [14]. Orbital involvement may vary between 66% and 100% [17]. Manifestations of orbital spread include periorbital swelling, palpebral abscess, orbital cellulitis, proptosis, chemosis, reduced vision, vitritis, endophthalmitis, orbital apex syndrome and ophthalmoplegia [15]. Blindness, a major complication of ROCM, may result from optic nerve infarction due to central retinal artery/ophthalmic artery occlusion or involvement of the orbital apex [17]. Intracranial progression may occur by direct extension or angioinvasion, usually within the span of days [18]. Nearly all patients have orbital involvement by the time intracranial disease is diagnosed [15]. Intracranial spread is heralded by signs of cavernous sinus thrombosis, hemiparesis, altered mentation and focal seizures [16].
Diagnosis
Direct microscopy, histopathology and fungal culture of surgical specimens form the cornerstones in the diagnosis of MCR. Hyphae of Mucorales demonstrate a broad (6–25 μm), non-septate, branching (90◦ bifurcations) morphology and can be detected using direct microscopy or on a potassium hydroxide (KOH) wet mount preparation (Fig. 2) [19]. Neutrophilic or granulomatous inflammation is the predominant finding on histopathology. Prominent necrosis and angioinvasion are common [19] (Fig. 3). Histopathological tissue diagnosis is still one of the most accurate and fast diagnostic modalities for MCR. All Mucorales species grow rapidly [3–7 days] on Sabouraud dextrose agar at a temperature of 25–30 °C [19] (Fig. 4). Recently introduced molecular assays, using polymerase chain reaction (PCR)-based techniques, aid in rapid diagnosis and speciation of Mucorales from a variety of specimen [8].
Treatment
Effective treatment of ROCM requires high index of clinical suspicion, expeditious laboratory and radiological diagnosis as well as a multidisciplinary management. Antifungal therapy using 5–10 mg/kg of liposomal amphotericin B, aggressive surgical debridement and elimination of the underlying risk factors are key in the effective management of ROCM [20]. Surgical management includes extensive debridement along with turbinectomy, palatal resection, lamina papyracea resection and occasionally orbital exenteration. Retro-bulbar injection and/or sinus irrigation with 3.5 mg/ml and 1 mg/ml, respectively, using amphotericin B may be performed. Following clinical and radiological stabilisation or regression of the disease, medical management may be subsequently stepped down to oral isavuconazole or oral posaconazole [20].
Prognosis
Prognosis of ROCM is dismal, even with aggressive surgical and medical treatment. Mortality of ROCM varies between 25% and 80% and depends of on the extent of the disease, promptness of treatment and underlying risk factors. In a prospective study by Chamilos et al., the survival rate was found to be 85% when treatment was initiated within 5 days of diagnosis as compared to 49% when treatment was started following the 6th day [21]. Combination of surgical and medical therapy has been associated with better survival (70%) as compared to only surgical management (57%) or only antifungal chemotherapy (61%) [21].
As the situation of concomitant ROCM and COVID-19 still evolves, it is difficult to ascertain the exact mortality rate. The mortality rate of CAM in general is estimated to range between 28 and 52% in different studies [10]. A more extensive case series would be necessary to estimate the mortality of ROCM–COVID-19 co-infection.
Imaging of Rhino-orbito-cerebral Mucormycosis
CT and MRI help in making an early pre-operative diagnosis of ROCM. Imaging plays a vital role in evaluation of disease spread which in turn guides medical and surgical management. CT is quick and readily available; common findings include opacification of the sinonasal air spaces and obliteration of the deep neck fat pads. Bone destruction, if any, is best identified on CT bone algorithms. MRI, with its excellent inherent soft tissue resolution, helps in characterising sinonasal contents, involvement of the deep neck soft tissues and spaces as well as identify perineural and intracranial spread. In an appropriate clinical setting, the imaging features of ROCM are diagnostic [22].
For the ease of reporting, we classify ROCM into 2 broad categories, based on anatomic involvement: sinonasal (nasal cavity and paranasal sinuses) and extra-sinus (deep neck, orbital and intracranial) involvement. A detailed account of the previously reported literature and pertinent imaging features of ROCM is presented.
Sinonasal involvement
ROCM typically begins in the nasal mucosa and spreads into the paranasal sinuses [23]. CT findings of nasal MCR are non-specific and sparsely reported. In a study to characterise CT findings in invasive fungal sinusitis (IFS) (mucormycosis, aspergillosis), DelGaudio et al. found severe thickening of the nasal mucosa, turbinates, septum and nasal floor in 91% (21/23) patients [24]. CT may also reveal isolated, non-specific turbinate hypertrophy with/without inflammatory fluid [2]. Nasal septal perforation has been identified by Therakathu et al. in ROCM [2].
At MRI, the involved nasal mucosa may demonstrate varied signals, including hyperintensity (necrosis) or hypointensity (fungal paramagnetic material) on T2W images [2, 25]. Safder et al. reported 2 cases with restricted diffusion, in the turbinates and mucoperiosteal thickening within the maxillary sinus, representing infarcted tissue [25]. Necrosis and devitalisation of the turbinates may cause lack of contrast enhancement on MRI. This appearance is termed as the “black turbinate (BT) sign” [25] (Fig. 5). The BT sign was first described in nasal MCR, but subsequently reported in other cases of IFS [25, 26].
It is worthwhile to note that this imaging appearance has been identified in normal subjects as well [33]. The lack of enhancement in normal subjects is linked to the normal cavernous tissues within the turbinates [27]. Involvement of the posterior portions of the inferior and middle turbinates, well-defined margins, hyperintense T2 signals, thin peripheral enhancement, progressive enhancement on dynamic contrast-enhanced scans and T2 hyperintensity favour benign BT [27]. On the contrary, fungal BTs are confluent, ill defined, non-enhancing masses commonly involving the middle turbinate (because they filter majority of nasal airflow) [27, 28].
Involvement of the paranasal sinuses is common. In studies on ROCM, Bhansali et al., Ferry et al. and Yohai et al. reported PNS involvement in 100%, 69% and 79% patients, respectively [23, 29, 30]. Some authors identify the maxillary sinus to be most frequently involved; others suggest the ethmoid sinuses [2, 22]. Involvement of multiple sinuses is common; maxillary, ethmoid and sphenoid sinuses being a common combination [2]. In a study on 43 patients with proven ROCM by Therakathu et al., unilateral sinus involvement was found to be more common; however, in another study by Slonimsky et al. bilateral sinonasal involvement was found more in ROCM than aspergillosis [2, 31].
CT features of paranasal sinus disease in ROCM include a rind of soft tissue, dense opacification or variable, nodular, mucoperiosteal thickening [28, 31]. The presence of air fluid levels have been disputed in the literature [22, 25, 32]. Radiodense concretions, common in aspergillosis, are not seen in ROCM [33]. MRI signals of the sinus contents may vary, ranging from hyperintensity to profound hypointensity (due to fungal paramagnetic contents) on T2W images [22, 32] Contrast-enhanced scans also reveal range of enhancement patterns, including absent to heterogeneous intense enhancement [2] (Fig. 6). Bacterial sinusitis lacks local necrosis, hence, the mucosal T2 signals and enhancement are not affected [34].
Extra-sinus spread
Extra-sinus extension of the MCR is common, often without radiological evidence of bony sinus wall destruction [32]. Bone destruction in the ROCM has been found in only 40% cases [16]. The angioinvasive propensity of the fungus, and its ability to disseminate along the perivascular channels, allows the invasion of adjacent structures through intact bony partitions [35] (Fig. 7). If involved, the bones may show rarefaction, erosions or permeative destruction on a CT scan [2].
Deep neck involvement
Stranding and/or soft tissue obliteration of the fat planes are important signs of fungal spread into the deep neck spaces [36]. Involvement of the distinct fat planes anterior and posterior to the maxillary sinus (anterior periantral fat and posterior periantral/retro-antral fat, respectively) is common. Retro-antral fat involvement is considered to be one of the initial imaging signs of deep neck invasion in ROCM [37, 38] (Fig. 8). Stranding or soft tissue in the periantral region is thought to be due to congestive oedema secondary to vascular thrombosis or the presence of fungal elements due to spread along blood vessels and perivascular spaces across the confines of the maxillary sinus [37]. Irrespective of the nature of the soft tissue, this region is an important review area, especially if dedicated CT/MRI of the neck is not performed.
The pterygopalatine fossa (PPF) may also be involved, due to spread from the nasal cavity via the sphenopalatine foramen [39]. Middlebrooks et al. suggested that involvement of the PPF correlated strongly with acute IFS (r = 0.64) and sphenopalatine foramen involvement was present in 72% of patients [40].
Normally, fat is seen around the branches of the internal maxillary artery in the PPF [36]. Obliteration of this fat must raise suspicion for extension of the infection [36] (Fig. 9). In our literature search, involvement of the deep neck spaces, including the PPF, have only occasionally been alluded to. In a case series of 10 patients with ROCM, involvement of the PPF was seen in all patients. Accounting for this, the authors suggested routine exploration of the PPF during surgical debridement in patients with ROCM [39]. Owing to the aggressive spread of MCR and the extensive communication of the PPF with other vital structures (oral cavity, orbit, middle cranial fossa), we recommend inclusion of dedicated neck imaging studies in all patients with suspected ROCM coupled with a thorough evaluation of the PPF in each case (Fig. 10).
In furtherance of the review of the deep neck spaces, we also suggest evaluation of the skull base. Skull base osteomyelitis (SBO) is rare in ROCM, even in the presence of deep neck involvement [22]. SBO in ROCM has been recorded in the chronic phase of the infection [2, 22]. However, we encountered one patient presenting with acute cranial nerve palsies with radiological evidence as well as pathologically proven SBO (Fig. 11). Marrow signal alterations, seen as hypointense on T1W and hyperintense on STIR images, are features typical of SBO [22, 41]. MCR-related SBO may reveal abnormal heterogeneous marrow enhancement with non-enhancing areas representing devitalised bone on contrast-enhanced (CE) MRI [41].
A thorough evaluation of the deep neck spaces and the skull base also entails evaluation of the peripheral nerves and skull base foramina [42]. Perineural involvement in ROCM constitutes an important pathway of intracranial spread. In a retrospective histopathological review of 11 patients with ROCM, 8 out of 9 specimens with neural tissue showed evidence of perineural spread [43]. In another pathological analysis of ROCM, 19 biopsied peripheral nerves yielded evidence of perineural spread in 15 samples (72.1%) [44]. The cause perineural spread of MCR is unknown, but thought to be related to a favourable intraneural microenvironment and neurotropic factors (secreted within the nerves) [44]. Only a limited number of cases have reported radiological evidence of perineural spread, the trigeminal nerve being most commonly involved [42, 45, 46]. With the sparse reported radiological data, it can be assumed that perineural spread shows imaging patterns similar to head and neck malignancies, including obliteration of perineural fat pads, nerve enhancement and widening of the skull base foramen [46, 47] (Fig. 12).
Orbital involvement
Orbital involvement results from spread of MCR via the nasolacrimal duct and lamina papyracea [23]. Spread may also occur from the PPF via the inferior orbital fissure [39]. Independent studies on ROCM, yielded an incidence of orbital invasion ranging between 76 and 80% [2, 23].
Orbital soft tissue, similar to PNS contents, is a typical imaging feature of intraorbital MCR spread [2]. Orbital fat stranding, including the retro-bulbar region, as well as thickening and/or displacement of the medial rectus (indicating spread from ethmoid sinuses) are also frequently encountered [22, 48] (Fig. 13). Proptosis may occur due to retro-bulbar inflammation and/or orbital apex involvement [22, 39]. Orbital apex involvement occurs due to spread from the sphenoid sinuses and forms an important conduit for intracranial spread [49]. MCR is the most common aetiology of orbital apex syndrome among all fungal infections [49].
Occlusion of the orbital vessels (superior ophthalmic vein, ophthalmic artery), due to MCR-related vasculitis and thrombosis, may also be noted [22]. The occlusion of the ophthalmic artery and/or central retinal artery may result in optic nerve infarction (ONI). In our literature review, we found 7 previously published reports of ONI in patients with ROCM [50–56]. Of these, there were 2 reports of bilateral ONI and 1 report of ONI being the initial presentation of orbital MCR [51, 52, 55]. Infarcted optic nerves demonstrates restricted diffusion and normal FLAIR signals on MRI [51] (Fig. 14).
Intracranial spread
Neuroparenchymal involvement
The anterior cranial fossa is the typical site of MCR involvement. Spread occurs through erosions of the cribriform plate or via perineural spread along the olfactory nerves [57]. The olfactory nerves, with their projections into the paleocortex (basifrontal lobe) and the neocortex (mesial temporal lobe), serve as important conduits for preferential involvement of these region [58]. Involved olfactory nerves appear thickened and hypointense on T2W images [58].
Neuroparenchymal infection begins with cerebritis, seen as cortical/subcortical areas of T2/FLAIR hyperintensity with or without contrast enhancement. This stage may eventually progress to a peripherally enhancing abscess with contents demonstrating restricted diffusion and T2 hypointensity (attributable paramagnetic fungal material) [57] (Fig. 15). MR spectroscopy may help in narrowing down to a diagnosis; elevated lactate and trehalose (3.8 ppm) have been described [59, 60]. The lack valine and isoleucine (0.9 ppm) and leucine (3.6 ppm), seen in the bacterial abscesses, may help guide the radiologist towards MCR [59]. MR spectroscopy however needs further validation with a larger case-based series.
Neurovascular complications
Vascular involvement is the most dreaded complication of MCR due to the associated poor prognosis. In a meta-analysis performed by Mazzai et al., 42 cases of MCR-related vascular complications were identified between 1975 and 2019. Outcome of their research revealed 35 cases of arterial and/or cavernous sinus thrombosis with cerebral ischaemia; 6 cases of subarachnoid haemorrhage; 5 cases of arterial aneurysms; and 1 case of septic emboli. Of these, only 9 patients survived [57].
Cavernous sinus thrombosis is common, occurring due to spread of MCR from the orbit, across the orbital apex [23]. On MRI, a thrombosed cavernous sinus demonstrates loss of flow voids on T1W and T2W images with a convexity along its lateral margin. CE examinations reveal filling defects within an otherwise enhancing sinus [23, 57] (Fig. 16). Intracranial spread may also result in occlusion of the surface veins and dural venous sinuses (especially the superior sagittal sinus). Such occlusions may result in venous ischaemia with/without haemorrhagic conversion. “Blooming” on gradient echo or susceptibility weighted images SWI must raise concern for a venous occlusion and prompt confirmation with a venogram study [57, 61].
Arterial occlusions may secondary to cavernous sinus invasion/thrombosis (internal carotid artery) and leptomeningeal disease or due to direct spread from the sphenoid sinus (basilar artery) [57]. The high propensity for arterial invasion by MCR is due to its ability to reproduce in the internal elastic layer of the vessel, causing separation of the elastic and middle layers leading to intimal damage and thrombosis [62]. Ma et al. also report purulent arteritis and inflammatory emboli caused by arterial invasion by MCR, thus leading to cerebral infarction or mycotic aneurysm [63].
Unenhanced CT in an acute setting or diffusion weighted imaging help in identifying neuroparenchymal infarction. Loss of arterial flow voids on T1W and T2W images must raise the suspicion for a thrombo-occlusion. Intra-arterial hypointensity on SWI suggests the presence of a thrombus. CT or MR angiograms can help detected the site of the occlusion. MRI vessel wall imaging may reveal abnormal enhancement of the arterial wall with a non-enhancing intraluminal thrombus [57] (Fig. 17).
It must be noted that vascular complications of MCR are not limited to thrombo-occlusions [50]. Mycotic aneurysms are associated with an increased mortality, and hence, an active, thorough search must be performed on angiogram studies (57). Rupture of mycotic aneurysm results in subarachnoid haemorrhage, seen as hyperdensity and susceptibility in the CSF spaces on CT and SWI imaging, respectively.
Conclusion
ROCM is a common cause of IFS in diabetics and immunocompromised patients. Since 2020, ROCM co-infection has been identified in COVID-19 patients, challenging patient management. ROCM presents with a fulminant clinical course, needing prompt and aggressive treatment. Imaging provides rapid diagnosis and plays a crucial role in delineating spread of the disease, thus guiding surgical interventions. The BT sign is a common finding in most patients with ROCM, but it may be seen in other IFS and may also be mimicked by normal cavernous tissues in the turbinates. The angioinvasive property of the fungus facilitates spread beyond the sinus without overt bone destruction. Thus, extension of MCR into the neck spaces and the orbits occurs early in the disease; fat stranding may be the only imaging evidence of extra-sinus spread. Hence, close evaluation of soft tissue algorithms on CT and fat-suppressed sequences on MRI is imperative in detection. Additional detailed imaging of the base of skull must be considered in suspected cases of MCR as the fungus has the potential to spread along peripheral nerves in the base of the skull into the intracranial compartment. Intracranial manifestations of the infection vary; ranging from abscess formation to vasculitis-related ischaemic complications, all of which are harbingers of a poor outcome. Knowledge of these imaging manifestations with an algorithmic approach in evaluation of disease ensures a thorough evaluation of each case which impacts patient care and outcome.
Abbreviations
- BT
Black turbinate
- CAM
Coronavirus disease 2019 (COVID-19)-associated Mucormycosis
- CE
Contrast-enhanced
- COVID-19
Coronavirus disease 2019
- DM
Diabetes mellitus
- FS
Fat-suppressed
- HE
Haematoxylin and Eosin
- IFS
Invasive fungal sinusitis
- MCR
Mucormycosis
- ONI
Optic nerve infarction
- PPF
Pterygopalatine fossa
- ROCM
Rhino-orbito-cerebral Mucormycosis
- SBO
Skull base osteomyelitis
Authors' contributions
VP is the guarantor of integrity of study and contributed to the study concept and design, analysis of the data, manuscript preparation and literature search. RS contributed to the image preparation, analysis of the data, manuscript review and literature search. RK contributed to histopathology examination, manuscript review and literature search. SCB contributed to the microbiology examination, manuscript review and literature search. BP contributed to the study concept and design, literature search and manuscript revision. All authors read and approved the final manuscript.
Funding
This work was not sponsored by grants or any funding organisation or company.
Availability of data and materials
All data are included in this manuscript.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
Vivek Pai is member of the Insights into Imaging Editorial Board. He has not taken part in the review or selection process of this article. The remaining authors declare that they have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Chung JH, Godwin JD, Chien JW, Pipavath SJ. Case 160: pulmonary mucormycosis. Radiology. 2010;256(2):667–670. doi: 10.1148/radiol.10081907. [DOI] [PubMed] [Google Scholar]
- 2.Therakathu J, Prabhu S, Irodi A, Sudhakar SV, Yadav VK, Rupa V. Imaging features of rhinocerebral mucormycosis: a study of 43 patients. Egypt J Radiol Nucl Med. 2018;49(2):447–452. [Google Scholar]
- 3.Agrawal R, Yeldandi A, Savas H, Parekh ND, Lombardi PJ, Hart EM. Pulmonary mucormycosis: risk factors, radiologic findings, and pathologic correlation. Radiographics. 2020;40(3):656–666. doi: 10.1148/rg.2020190156. [DOI] [PubMed] [Google Scholar]
- 4.Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26. doi: 10.3390/jof5010026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(1):16–S22. doi: 10.1093/cid/cir865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab. 2012;38(3):193–204. doi: 10.1016/j.diabet.2012.01.002. [DOI] [PubMed] [Google Scholar]
- 7.Spellberg B, Edwards J, Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–569. doi: 10.1128/CMR.18.3.556-569.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6(4):265. doi: 10.3390/jof6040265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia. 2020 doi: 10.1007/s11046-020-00472-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020 doi: 10.1007/s11046-020-00462-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sarda R, Swain S, Ray A, Wig N. COVID-19 associated mucormycosis: an epidemic within a pandemic. QJM. 2021 doi: 10.1093/qjmed/hcab165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi. 2021;7(4):298. doi: 10.3390/jof7040298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Banerjee M, Pal R, Bhadada S. Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad Med J. 2021 doi: 10.1136/postgradmedj-2021-140537. [DOI] [PubMed] [Google Scholar]
- 14.Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69(2):244–252. doi: 10.4103/ijo.IJO_3774_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mallis A, Mastronikolis SN, Naxakis SS, Papadas AT. Rhinocerebral mucormycosis: an update. Eur Rev Med Pharmacol Sci. 2010;14:987–992. [PubMed] [Google Scholar]
- 16.Wali U, Balkhair A, Al-Mujaini A. Cerebro-rhino orbital mucormycosis: an update. J Infect Public Health. 2012;5(2):116–126. doi: 10.1016/j.jiph.2012.01.003. [DOI] [PubMed] [Google Scholar]
- 17.Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi. 2019;5(3):59. doi: 10.3390/jof5030059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Munir N, Jones N. Rhinocerebral mucormycosis with orbital and intracranial extension: a case report and review of optimum management. J Laryngol Otol. 2007;121(2):192–195. doi: 10.1017/S0022215106003409. [DOI] [PubMed] [Google Scholar]
- 19.Reid G, Lynch JP, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med. 2020;41(01):099–114. doi: 10.1055/s-0039-3401992. [DOI] [PubMed] [Google Scholar]
- 20.Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(1):S93–S101. doi: 10.1093/mmy/myx101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol. 2021;69(6):1361. doi: 10.4103/ijo.IJO_1165_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–509. doi: 10.1086/590004. [DOI] [PubMed] [Google Scholar]
- 23.Chan LL, Singh S, Jones D, Diaz EM, Jr, Ginsberg L. Imaging of mucormycosis skull base osteomyelitis. AJNR Am J Neuroradiol. 2000;21(5):828–831. [PMC free article] [PubMed] [Google Scholar]
- 24.Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J. 2004;80(949):670–674. doi: 10.1136/pgmj.2003.016030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.DelGaudio JM, Swain RE, Jr, Kingdom TT, Muller S, Hudgins PA. Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg. 2003;129(2):236. doi: 10.1001/archotol.129.2.236. [DOI] [PubMed] [Google Scholar]
- 26.Safder S, Carpenter JS, Roberts TD, Bailey N. The “Black Turbinate” sign: an early MR imaging finding of nasal mucormycosis. AJNR Am J Neuroradiol. 2009;31(4):771–774. doi: 10.3174/ajnr.A1808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Horger M, Hebart H, Schimmel H, et al. Disseminated mucormycosis in haematological patients: CT and MRI findings with pathological correlation. Br J Radiol. 2006;79(945):88–e95. doi: 10.1259/bjr/16038097. [DOI] [PubMed] [Google Scholar]
- 28.Han Q, Escott E. The black turbinate sign, a potential diagnostic pitfall: evaluation of the normal enhancement patterns of the nasal turbinates. AJNR Am J Neuroradiol. 2019;40(5):855–861. doi: 10.3174/ajnr.A6037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Gillespie MB, O'Malley BW, Jr, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg. 1998;124:520–526. doi: 10.1001/archotol.124.5.520. [DOI] [PubMed] [Google Scholar]
- 30.Ferry AP, Abedi S. Diagnosis and management of rhino-orbitocerebral mucormycosis (phycomycosis): a report of 16 personally observed cases. Ophthalmology. 1983;90(9):1096–1104. doi: 10.1016/s0161-6420(83)80052-9. [DOI] [PubMed] [Google Scholar]
- 31.Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39(1):3–22. doi: 10.1016/s0039-6257(05)80041-4. [DOI] [PubMed] [Google Scholar]
- 32.Slonimsky G, McGinn JD, Goyal N, et al. A model for classification of invasive fungal rhinosinusitis by computed tomography. Sci Rep. 2020;10(1):12591. doi: 10.1038/s41598-020-69446-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Rumboldt Z, Castillo M. Indolent intracranial mucormycosis: case report. AJNR Am J Neuroradiol. 2002;23(6):932–934. [PMC free article] [PubMed] [Google Scholar]
- 34.Peterson KL, Wong M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107:855–862. doi: 10.1097/00005537-199707000-00004. [DOI] [PubMed] [Google Scholar]
- 35.Nunes DM, Rocha AJ, Rosa Júnior MR, da Silva CJ. “Black turbinate sign”: a potential predictor of mucormycosis in cavernous sinus thrombophlebitis. Arq Neuropsiquiatr. 2012;70(1):78. doi: 10.1590/s0004-282x2012000100019. [DOI] [PubMed] [Google Scholar]
- 36.Aribandi M, McCoy VA, Bazan C. Imaging features of invasive and noninvasive fungal sinusitis: a review. Radiographics. 2007;27(5):1283–1296. doi: 10.1148/rg.275065189. [DOI] [PubMed] [Google Scholar]
- 37.Gamba JL, Woodruff WW, Djang WT, Yeates AE. Craniofacial mucormycosis: assessment with CT. Radiology. 1986;160(1):207–212. doi: 10.1148/radiology.160.1.3715034. [DOI] [PubMed] [Google Scholar]
- 38.Silverman CS, Mancuso AA. Periantral soft-tissue infiltration and its relevance to the early detection of invasive fungal sinusitis: CT and MR findings. AJNR Am J Neuroradiol. 1998;19:321–325. [PMC free article] [PubMed] [Google Scholar]
- 39.Mossa-Basha M, Turan Ilıca A, Maluf F, Karakoç O, İzbudak I, Aygün N. The many faces of fungal disease of the paranasal sinuses: CT and MRI findings. Diagn Interv Radiol. 2013;19:195–200. doi: 10.5152/dir.2012.003. [DOI] [PubMed] [Google Scholar]
- 40.Hosseini SMS, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol. 2005;262(11):932–938. doi: 10.1007/s00405-005-0919-0. [DOI] [PubMed] [Google Scholar]
- 41.Middlebrooks EH, Frost CJ, De Jesus RO, Massini TC, Schmalfuss IM, Mancuso AA. Acute invasive fungal rhinosinusitis: a comprehensive update of CT findings and design of an effective diagnostic imaging model. AJNR Am J Neuroradiol. 2015;36(8):1529–1535. doi: 10.3174/ajnr.A4298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chapman PR, Choudhary G, Singhal A. Skull base osteomyelitis: a comprehensive imaging review. AJNR Am J Neuroradiol. 2021;42(3):404–413. doi: 10.3174/ajnr.A7015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.McLean FM, Ginsberg LE, Stanton CA. Perineural spread of rhinocerebral mucormycosis. AJNR Am J Neuroradiol. 1996;17:114–116. [PMC free article] [PubMed] [Google Scholar]
- 44.Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis. Emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001;125:375–378. doi: 10.5858/2001-125-0375-HFOZ. [DOI] [PubMed] [Google Scholar]
- 45.Sravani T, Uppin SG, Uppin MS, Sundaram C. Rhinocerebral mucormycosis: pathology revisited with emphasis on perineural spread. Neurol India. 2014;62(4):383–386. doi: 10.4103/0028-3886.141252. [DOI] [PubMed] [Google Scholar]
- 46.Press GA, Weindling SM, Hesselink JR, Ochi JW, Harris JP. Rhinocerebral mucormycosis: MR manifestations. J Comput Assist Tomogr. 1988;12:744–749. doi: 10.1097/00004728-198809010-00005. [DOI] [PubMed] [Google Scholar]
- 47.Orguc S, Yücetürk AV, Akif Demir M, Goktan C. Rhinocerebral mucormycosis: Perineural spread via the trigeminal nerve. J Clin Neurosci. 2005;12(4):484–486. doi: 10.1016/j.jocn.2004.07.015. [DOI] [PubMed] [Google Scholar]
- 48.Dankbaar JW, Pameijer FA, Hendrikse J, Schmalfuss IM. Easily detected signs of perineural tumour spread in head and neck cancer. Insights Imaging. 2018;9:1089–1095. doi: 10.1007/s13244-018-0672-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Bae MS, Kim EJ, Lee KM, Choi WS. Rapidly progressive rhino-orbito-cerebral mucormycosis complicated with unilateral internal carotid artery occlusion: a case report. Neurointervention. 2012;7(1):45–49. doi: 10.5469/neuroint.2012.7.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Anders UM, Taylor EJ, Martel JR, Martel JB. Acute orbital apex syndrome and rhino-orbito-cerebral mucormycosis. Int Med Case Rep J. 2015;8:93–96. doi: 10.2147/IMCRJ.S83036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Chaulk AL, Do TH, Supsupin EP, Bhattacharjee MB, Richani K, Adesina OOO. A unique radiologic case of optic nerve infarction in a patient with mucormycosis. J Neuroophthalmol. 2021 doi: 10.1097/WNO.0000000000001179. [DOI] [PubMed] [Google Scholar]
- 52.Ghuman MS, Kaur S, Bhandal SK, Ahluwalia A, Saggar K. Bilateral optic nerve infarction in rhino-cerebral mucormycosis: A rare magnetic resonance imaging finding. J Neurosci Rural Pract. 2015;6(3):403–404. doi: 10.4103/0976-3147.158790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Alsuhaibani AH, Al-Thubaiti G, Al Badr FB. Optic nerve thickening and infarction as the first evidence of orbital involvement with mucormycosis. Middle East Afr J Ophthalmol. 2012;19(3):340–342. doi: 10.4103/0974-9233.97957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Mathur S, Karimi A, Mafee MF. Acute optic nerve infarction demonstrated by diffusion-weighted imaging in a case of rhinocerebral mucormycosis. AJNR Am J Neuroradiol. 2007;28(3):489–490. [PMC free article] [PubMed] [Google Scholar]
- 55.Lee BL, Holland GN, Glasgow BJ. Chiasmal infarction and sudden blindness caused by mucormycosis in AIDS and diabetes mellitus. Am J Ophthalmol. 1996;122(6):895–896. doi: 10.1016/s0002-9394(14)70392-7. [DOI] [PubMed] [Google Scholar]
- 56.Merkler AE, Duggal I, Kaunzner U, et al. Rapidly progressive bilateral optic nerve and retinal infarctions due to rhinocerebral mucormycosis and pseudoephedrine use. Neurol Clin Pract. 2016;6(6):549–552. doi: 10.1212/CPJ.0000000000000253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Borruat FX, Bogousslavsky J, Uffer S, Klainguti G, Schatz NJ. Orbital infarction syndrome. Ophthalmology. 1993;100(4):562–568. doi: 10.1016/s0161-6420(93)31606-4. [DOI] [PubMed] [Google Scholar]
- 58.Mazzai L, Anglani M, Giraudo C, Martucci M, Cester G, Causin F. Imaging features of rhinocerebral mucormycosis: from onset to vascular complications. Acta Radiol. 2021 doi: 10.1177/0284185120988828. [DOI] [PubMed] [Google Scholar]
- 59.Sandron J, Hantson Ph, Duprez T. Intracranial brain parenchymal spread of mucormycosis through olfactory tract: a diffusion-weighted imaging-based concept. Acta Radiol Open. 2020;9(12):2058460120980999. doi: 10.1177/2058460120980999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Siegal JA, Cacayorinb ED, Nassif AS, et al. Cerebral mucormycosis: proton MR spectroscopy and MR imaging. Magn Reson Imaging. 2000;18(7):915–920. doi: 10.1016/s0730-725x(00)00180-6. [DOI] [PubMed] [Google Scholar]
- 61.Maheshwari S, Patil M, Shendey S. Mucormycosis creeping along the nerves in an immunocompetent individual. J Radiol Case Rep. 2019;13(10):1–10. doi: 10.3941/jrcr.v13i10.3671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Pai V, Khan I, Sitoh YY, Purohit B. Pearls and pitfalls in the magnetic resonance diagnosis of dural sinus thrombosis: a comprehensive guide for the trainee radiologist. J Clin Imaging Sci. 2020;10:77. doi: 10.25259/JCIS_187_2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Ma J, Jia R, Li J, et al. Retrospective clinical study of eighty-one cases of intracranial mucormycosis. J Glob Infect Dis. 2015;7(4):143–150. doi: 10.4103/0974-777X.170497. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data are included in this manuscript.